Blood Knows What X-Rays Cannot See
When Dr. Apurba Ganguly began his research into musculoskeletal disease in 1989, he started with a question that conventional orthopaedics had never adequately answered: if two patients have identical X-ray findings — the same grade of osteoarthritis, the same joint space loss — why does one deteriorate rapidly while the other remains stable for years?
The answer was in the blood. Specifically, in the constellation of protein markers that reflect the biochemical state of the joint environment: the inflammatory cytokines driving tissue destruction, the enzyme levels reflecting cartilage breakdown rate, the metabolic indicators showing whether the body has the nutritional and biochemical resources to repair itself.
This insight — that chronic pain is fundamentally a biochemical phenomenon that can be read from the blood — led directly to the development of OPTM's diagnostic protocol. Over 35 years, we refined the biomarker panel from an initial 5 markers to the current 14+ marker comprehensive analysis, and developed the AI engine that interprets these results against the backdrop of over 1.2 lakh patient cases.
The result is a diagnostic system with 97% accuracy in identifying the primary metabolic driver of a patient's pain — compared to 60% for standard orthopaedic imaging. The difference represents tens of thousands of patients who would receive precisely the wrong treatment under the conventional diagnostic model.
For the patient, this means one thing: when OPTM designs your treatment protocol, it is targeting the actual cause of your pain — not the statistical average cause, not the most common cause, but your specific cause. This is why our outcomes consistently outperform those of generic pain management protocols.
Related Clinical Resources
